Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
02/2003
02/20/2003WO2003013578A1 Omoxin agonists and antagonists for use in the treatment of metabolic disorders
02/20/2003WO2003013577A2 Use of il-18 inhibitors in hypersensitivity disorders
02/20/2003WO2003013576A1 Regulation of the apj receptor for use in the treatment or prophylaxis of cardiac diseases
02/20/2003WO2003013575A1 Modulation of leukocyte-endothelial interactions following ischemia
02/20/2003WO2003013574A1 Melanin-concentrating hormone antagonists
02/20/2003WO2003013573A1 Polypeptide conjugates with extended circulating half-lives
02/20/2003WO2003013572A1 Treatment of tuberculosis using immunomodulator compounds
02/20/2003WO2003013571A1 Peptidomimetics of biologically active metallopeptides
02/20/2003WO2003013570A1 Platelet-derived growth factor protection of cardiac myocardium
02/20/2003WO2003013569A2 Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
02/20/2003WO2003013568A1 Cytokine modulation therapy
02/20/2003WO2003013545A1 Novel benzo-fused heterocycles as endothelin antagonisits
02/20/2003WO2003013537A2 Irinotecan for treatment of cancer
02/20/2003WO2003013536A2 Methods for treatment of cancer using irinotecan based on ugt1a1
02/20/2003WO2003013535A2 Use of irinotecan for improved treatment of cancer based on mdr1
02/20/2003WO2003013534A2 Methods for the treatment of cancer with irinotecan based on cyp3a5
02/20/2003WO2003013533A2 Methods for improved treatment of cancer with irinotecan based on mrp1
02/20/2003WO2003013511A1 Integrin inhibitors for the treatment of eye diseases
02/20/2003WO2003013486A1 The treatment of lipodystrophy
02/20/2003WO2003013485A1 Inhibitors of hb-egf (erbb) receptors for treating myeloma
02/20/2003WO2003013483A1 Coated filter bag material for oral administration of medicament in liquid and methods of making same
02/20/2003WO2003013438A2 Nutrient therapy for immuno-compromised patients
02/20/2003WO2003013434A2 Methods and compositions for treating diseases associated with excesses in ace
02/20/2003WO2003013432A2 Methods of use for novel sulfur containing organic nitrate compounds
02/20/2003WO2003013431A2 Compositions and methods for the therapy and diagnosis of breast cancer
02/20/2003WO2003013429A2 A programmable electronic maze for use in the assessment of animal behaviour
02/20/2003WO2003013425A2 In vitro assays for inhibitors of hiv capsid conformational changes and for hiv capsid formation
02/20/2003WO2003013423A2 Antithrombotic agent
02/20/2003WO2003013422A2 Methods for the treatment and prognosis of leukemia and other cancer types
02/20/2003WO2003013244A1 Oral treatment of hemophilia
02/20/2003WO2003000851A3 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
02/20/2003WO2002099062A3 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
02/20/2003WO2002098900A3 Novel human proteins, polynucleotides encoding them and methods of using the same
02/20/2003WO2002098360A3 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
02/20/2003WO2002096927A3 Ribozyme based treatment of female reproductive diseases
02/20/2003WO2002094980A3 Phytocystatin
02/20/2003WO2002094874A3 Internalisation of virus into cells
02/20/2003WO2002094862A3 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
02/20/2003WO2002094200A3 Pulmonary administration of chemically modified insulin
02/20/2003WO2002092758A8 Gastrokines and derived peptides including inhibitors
02/20/2003WO2002089919A3 Usage of zinc for preventing tnf-induced pathology during cancer therapy
02/20/2003WO2002083733A3 Polynucleotides and polypeptides of the ifnalpha-6 gene
02/20/2003WO2002081628A3 Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
02/20/2003WO2002081621A3 Vaccine against the nile fever virus
02/20/2003WO2002079464A3 Viral vectors
02/20/2003WO2002079387A3 Modular molecular clasps and uses thereof
02/20/2003WO2002076437A3 Methods for treating neurodegenerative diseases including alzheimer's
02/20/2003WO2002074931A3 Inhibitors and disassemblers of fibrillogenesis
02/20/2003WO2002074331A3 Mutated mhc molecules for use in immune suppression
02/20/2003WO2002074156A3 Compositions and methods for the therapy and diagnosis of colon cancer
02/20/2003WO2002072019A3 Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
02/20/2003WO2002068673A3 Hin-1, a tumor suppressor gene
02/20/2003WO2002066505A3 Gmg-3, gmg-4, and gmg-6 polynucleotides and polypeptides and uses thereof
02/20/2003WO2002066062A3 Enhancement of glp-2 activity
02/20/2003WO2002064738A3 Modified target enzymes having catalytic triads and uses thereof
02/20/2003WO2002064021A3 Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity
02/20/2003WO2002061057A3 Regulation of human wee1-like serine/threonine protein kinase
02/20/2003WO2002058637A3 Compositions and methods for diagnosis of neuropsychiatric disorders
02/20/2003WO2002053170A3 Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo
02/20/2003WO2002047730A8 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
02/20/2003WO2002045738A3 Vaccine composition containing transforming growth factor alpha
02/20/2003WO2002042295A3 Peptides as met-ap2 inhibitors
02/20/2003WO2002029088A9 Highly expressible genes
02/20/2003WO2002028420A9 Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules
02/20/2003WO2002026950A3 Transferases
02/20/2003WO2002026193A9 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
02/20/2003WO2002022156A8 Topical formulations for delivery of interleukin-11
02/20/2003WO2002017955A9 Delivery system for heparin-binding growth factors
02/20/2003WO2002014368A8 Proteins and nucleic acids encoding the same
02/20/2003WO2002012328A3 Compositions and methods for the therapy and diagnosis of colon cancer
02/20/2003WO2002008268A3 Leucine-based motif and clostridial neurotoxins
02/20/2003WO2001072325A9 Methods of blocking tissue destruction by autoreactive t cells
02/20/2003WO2001066766A3 A matrix metalloproteinase (mmp-25) expressed in skin cell
02/20/2003WO2001064949A9 Diagnostics and therapeutics for glaucoma
02/20/2003WO2001057271A3 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human breast and bt 474 cells
02/20/2003US20030037350 Nucleotide sequences coding polypeptides for use in the treatment and diagnosis of cancer and nervous system disorders
02/20/2003US20030037334 Method and system for providing a customized media list
02/20/2003US20030036646 Uncoupling protein polynucleotides, polypeptides, and antibodies
02/20/2003US20030036645 Breast cancer resistance protein (BCRP) and the DNA which encode it
02/20/2003US20030036642 Platelet derived growth factor (PDGF) nucleic acid ligand complexes
02/20/2003US20030036638 Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
02/20/2003US20030036637 Purification of human serum albumin
02/20/2003US20030036634 Secreted and transmembrane polypeptides and nucleic acids encoding the same
02/20/2003US20030036633 DNA encoding bradykinin B1 receptor
02/20/2003US20030036632 Protein for use in the treatment of alzheimer's, muscle, nervous system and thrombocytopenia
02/20/2003US20030036631 Protein for use in the treatment of asthma, leukemia, or other allergic or inflammatory defects
02/20/2003US20030036628 p21 peptides
02/20/2003US20030036627 Peptide for use in the prevention and treatment of infections
02/20/2003US20030036568 Permeation enhancers
02/20/2003US20030036567 Propylene glycol as an agent to stimuate thrombopoiesis
02/20/2003US20030036546 Administering an opioidergic composition, such as opiate antagonist, an opiate agonist and a combination thereof.
02/20/2003US20030036526 Activating a signaling cascade comprising, introducing leptin and/or a cytokine to a receptor complex comprising gp 130, to genes in neuro- endocrine cells or cells of neuro-endocrine origin.
02/20/2003US20030036525 Hyaluronic acid and/or a salt thereof associated with/bound with an effective amount of anti-sense to the gene implicated in the disease or condition
02/20/2003US20030036514 Administering one or a mixture of a group of linear oligopeptides having from 7 to 10 units
02/20/2003US20030036512 A neurotrophic factor, such as brain-derived neurotrophic factor; treating leptin resistance caused hypertension, sterility, obesity, glucose metabolic abnormality, ischemic disease and growth hormone insufficiency
02/20/2003US20030036511 Preparation of pure isoforms using TSK sulfopropyl cation exchange chromatography and reverse phase high performance liquid chromatography.
02/20/2003US20030036510 Novel human cell division cycle proteins
02/20/2003US20030036509 TGF-alpha polypeptides, functional fragments and methods of use therefor
02/20/2003US20030036508 EGF motif protein, EGFL6 materials and methods
02/20/2003US20030036507 Urocortin-III and uses thereof
1 ... 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 ... 3163